Multiple Myeloma Therapeutics Market by Type (Chemotherapy, Radiation, Stem Cell Transplant & Supportive Treatment), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2024-2030

Multiple Myeloma Therapeutics Market by Type (Chemotherapy, Radiation, Stem Cell Transplant & Supportive Treatment), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2024-2030


The Multiple Myeloma Therapeutics Market size was estimated at USD 21.54 billion in 2023 and expected to reach USD 22.95 billion in 2024, at a CAGR 7.06% to reach USD 34.74 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multiple Myeloma Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multiple Myeloma Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multiple Myeloma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen, Inc., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline PLC, Innate Pharma SA, Johnson & Johnson Services, Inc., Kesios Therapeutics Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Multiple Myeloma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

Chemotherapy
Histone Deacetylase (HDAC) Inhibitors
Immunomodulating Agents
Monoclonal Antibodies
Proteasome Inhibitors
Traditional Chemotherapy

Radiation

Stem Cell Transplant & Supportive Treatment
Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies & Drug Stores
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multiple Myeloma Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multiple Myeloma Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Multiple Myeloma Therapeutics Market?
4. What is the market share of the leading vendors in the Multiple Myeloma Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Multiple Myeloma Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Multiple Myeloma Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the cases of blood cancers
5.1.1.2. Increasing geriatric population across the globe
5.1.1.3. Growing need for advanced therapeutics for multiple myeloma
5.1.2. Restraints
5.1.2.1. High cost associated with the treatment of multiple myeloma
5.1.3. Opportunities
5.1.3.1. Technological advancement in the multiple stem cell transplant procedures
5.1.3.2. Ongoing research and development activities in multiple myeloma therapeutics
5.1.4. Challenges
5.1.4.1. Strict rules and regulations of the government
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Multiple Myeloma Therapeutics Market, by Type
6.1. Introduction
6.2. Chemotherapy
6.3.1. Histone Deacetylase (HDAC) Inhibitors
6.3.2. Immunomodulating Agents
6.3.3. Monoclonal Antibodies
6.3.4. Proteasome Inhibitors
6.3.5. Traditional Chemotherapy
6.3. Radiation
6.4. Stem Cell Transplant & Supportive Treatment
7. Multiple Myeloma Therapeutics Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies & Drug Stores
8. Americas Multiple Myeloma Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Multiple Myeloma Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Multiple Myeloma Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Amgen, Inc.
12.1.3. Bristol-Myers Squibb Company
12.1.4. Celldex Therapeutics, Inc.
12.1.5. F. Hoffmann-La Roche Ltd.
12.1.6. Genzyme Corporation
12.1.7. GlaxoSmithKline PLC
12.1.8. Innate Pharma SA
12.1.9. Johnson & Johnson Services, Inc.
12.1.10. Kesios Therapeutics Ltd.
12.1.11. Merck & Co., Inc.
12.1.12. Novartis AG
12.1.13. Sanofi S.A.
12.1.14. Takeda Pharmaceutical Company Limited
12.1.15. Teva Pharmaceutical Industries Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MULTIPLE MYELOMA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings